Oruka Therapeutics (ORKA) Non-Current Deffered Revenue (2010 - 2018)
Oruka Therapeutics (ORKA) posted quarterly Non-Current Deffered Revenue of $4000.0 for Q3 2018, down 84.0% year-over-year from $25000.0 in Q3 2017, and down 55.56% quarter-over-quarter from $9000.0 in Q2 2018.
Oruka Therapeutics (ORKA) Non-Current Deffered Revenue (2010 - 2018) Analysis & Trends
Oruka Therapeutics' Non-Current Deffered Revenue history runs 9 years deep, the most recent figure standing at $4000.0 for Q3 2018.
- In Q3 2018, Non-Current Deffered Revenue fell 84.0% year-over-year to $4000.0; the TTM figure through Sep 2018 stood at $4000.0 (down 84.0% YoY), while the FY2017 annual figure was $20000.0, down 48.72% from the prior year.
- Non-Current Deffered Revenue for Q3 2018 stood at $4000.0, down from $9000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $47000.0 in Q2 2016, with the low at $1000.0 in Q1 2014.
- The 5-year median for Non-Current Deffered Revenue is $12000.0 (2018), against an average of $17375.0.
- The sharpest annual moves came in 2014 and 2016: Non-Current Deffered Revenue sank 87.5% in 2014, then surged 4600.0% in 2016.
- Oruka Therapeutics' Non-Current Deffered Revenue stood at $3000.0 in 2014, then slumped by 66.67% to $1000.0 in 2015, then jumped by 3800.0% to $39000.0 in 2016, then tumbled by 48.72% to $20000.0 in 2017, then tumbled by 80.0% to $4000.0 in 2018.
- Business Quant data shows ORKA's Non-Current Deffered Revenue at $4000.0 in Q3 2018, $9000.0 in Q2 2018, and $15000.0 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Oruka Therapeutics | 6.98 Bn | 5.25 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 4,000.00 |
| Jun 30, 2018 | 9,000.00 |
| Mar 31, 2018 | 15,000.00 |
| Dec 31, 2017 | 20,000.00 |
| Sep 30, 2017 | 25,000.00 |
| Jun 30, 2017 | 30,000.00 |
| Mar 31, 2017 | 35,000.00 |
| Dec 31, 2016 | 39,000.00 |
| Sep 30, 2016 | 43,000.00 |
| Jun 30, 2016 | 47,000.00 |
| Jun 30, 2015 | 1,000.00 |
| Mar 31, 2015 | 1,000.00 |
| Dec 31, 2014 | 3,000.00 |
| Sep 30, 2014 | 3,000.00 |
| Jun 30, 2014 | 2,000.00 |
| Mar 31, 2014 | 1,000.00 |
| Dec 31, 2013 | 1,000.00 |
| Jun 30, 2013 | 3,000.00 |
| Mar 31, 2013 | 8,000.00 |
| Dec 31, 2012 | 16,000.00 |